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I.  Introduction
The push to commercialize publicly funded, academy-driven scientifi c research has emerged as a signifi cant science policy challenge. 1 
Advocates of this push include Prime Minister Stephen Harper of Canada, 
who recently declared that “science powers commerce,”2 and President 
Barack Obama, who has urged Americans to “win the future” and claim 
“our generation’s Sputnik moment” by supporting government investment 
in scientifi c research that will create new industries and “countless new 
jobs” and make the US economy more competitive.3 Likewise, Prime 
Minister David Cameron, announcing a £180m “catalyst” grant for “new 
British ideas,” referred to the life sciences as “a jewel in the crown of [the 
1. Timothy Caulfi eld, “Talking Science – Commercialization Creep” (2012) 
34:1 Policy Options 20 [Caulfi eld, “Commercialization Creep”]; Timothy 
Caulfi eld, “Patents or Commercialization Pressure?: A (Speculative) 
Search for the Right Target” (2012) 22:1 Journal of Law, Information and 
Science 122; Timothy Caulfi eld & Ubaka Ogbogu, “Biomedical Research 
and the Commercialization Agenda: A Review of Main Considerations 
for Neuroscience” (2008) 15:4 Accountability in Research 303; Timothy 
Caulfi eld, “Stem Cell Research and Economic Promises” (2010) 38:2 JL 
Med & Ethics 303 [Caulfi eld, “Economic Promises”]; Jocelyn Downie 
& Matthew Herder, “Refl ections on the Commercialization of Research 
Conducted in Public Institutions in Canada” (2007) 1:1 McGill JL & 
Health 23.
2. Stephen Harper, “PM Announces Banting Postdoctoral Fellowships, 
Support for Next Einstein Initiative” (6 July 2010), online: Offi  ce of the 
Prime Minister <http://pm.gc.ca/eng/news/2010/07/06/pm-announces-
banting-postdoctoral-fellowships-support-next-einstein-initiative-0>.
3. Barack Obama, “Remarks by the President in State of Union Address” (25 
January 2011), online: Th e White House <http://www.whitehouse.gov/
the-press-offi  ce/2011/01/25/remarks-president-state-union-address>. 
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UK] economy” and called for a new model of research and development 
focused on “getting the best ideas through the proof of concept stage so 
we can get them into clinical development and get our entrepreneurs 
selling them around the world.”4 In the European Union, member states 
have announced reforms aimed at linking research innovation with 
“entrepreneurship, the business environment and the labour market, with 
a strong focus on better commercialization of research results.”5 Th ese 
claims and statements have generated some concern, especially regarding 
whether this “ever-intensifying pressure to commercialize research” 
overstates what scientifi c research can actually or realistically deliver.6 
As one critic has observed, key features of the commercialization trend, 
such as biotech start-ups and activities of university technology transfer 
offi  ces, resemble Ponzi schemes because they purport by “all appearances 
to be a success when careful measurement reveals … failure[s].”7
Th ere are, of course, arguments that can be put forward in support of 
both perspectives. Contemporary commercialization initiatives are chiefl y 
characterized by academy-industry partnerships, and public funding 
support for research projects that are able to obtain matching private 
sector funds, or that can show evidence of near-term commercializable 
outcomes (or at a minimum, a clear route to commercial exploitation). 8 
Th ese initiatives can and have produced benefi cial outcomes, including 
useful products, jobs, increased research funding and public-private 
sector linkages.9 However, these initiatives have also been linked with 
4. David Cameron, “PM Speech on Life Sciences and Opening Up the 
NHS” (6 December 2011), online: GOV.UK <https://www.gov.uk/
government/speeches/pm-speech-on-life-sciences-and-opening-up-the-
nhs>.
5. European Commission, “State of the Innovation Union 2012: 
Accelerating change” (21 March 2013), online: Innovation Union <http://
ec.europa.eu/research/innovation-union/pdf/state-of-the-union/2012/
state_of_the_innovation_union_report_2012.pdf> at 10.
6. Caulfi eld, “Commercialization Creep”, supra note 1 at 20.
7. Philip Mirowski, “Th e Modern Commercialization of Science is a Passel 
of Ponzi Schemes” (2012) 26:3-4 Social Epistemology 285 at 296.
8. Ubaka Ogbogu, “A Review of Pressing Ethical Issues Relevant to Stem 
Cell Translational Research” (2006) 14:3 Health Law Review 39.
9. Caulfi eld, “Commercialization Creep”, supra note 1; Ogbogu, ibid; 
Commission on the Future of Health Care in Canada, Building on Values: 
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adverse impacts on the integrity of scientifi c processes,10 scientifi c 
collaborations, exchanges and “open science” initiatives, 11 loss of 
public trust,12 hyped representations of research realities and outcomes 
Th e Future of Health Care in Canada (Saskatoon: Commission on the 
Future of Health Care in Canada, 2002).
10. Vincent Mangematin, Paul O’Reilly & James Cunningham, “PIs as 
Boundary Spanners, Science and Market Shapers” (2014) 39:1 Th e 
Journal of Technology Transfer 1; Riccardo Fini & Nicola Lacetera, 
“Diff erent Yokes for Diff erent Folks: Individual Preferences, Institutional 
Logics, and the Commercialization of Academic Research” in Gary D 
Libecap, Marie Th ursby & Sherry Hoskinson, eds, Spanning Boundaries 
and Disciplines: University Technology Commercialization in the Idea Age 
(Bingley, UK: Emerald Group, 2010) 1; Bertrand R Jordan & Daniel Fu 
Chang Tsai, “Whole-Genome Association Studies for Multigenic Diseases: 
Ethical Dilemmas Arising from Commercialization – Th e Case of Genetic 
Testing for Autism” (2010) 36:7 Journal of Medical Ethics 440; Philip 
Morowski, Science-Mart: Privatizing American Science (Cambridge, MA: 
Harvard University Press, 2011); Francesco Rentocchini et al, “Working 
Paper No. 2011/03:Th e Eff ect of Academic Consulting on Research 
Performance: Evidence from Five Spanish Universities” (2011), online: 
Ingenio Working Paper Series <http://www.ingenio.upv.es/sites/default/
fi les/working-paper/2011-03_-_the_eff ect_of_academic_consulting_on_
research_performance_evidence_from_fi ve_spanish_universities.pdf>.
11. Timothy Caulfi eld, Shawn HE Harmon & Yann Joly, “Open Science 
Versus Commercialization: A Modern Research Confl ict?” (2012) 
4:2 Genome Medicine 17; Tania Bubela et al, “Commercialization 
and Collaboration: Competing Policies in Publicly Funded Stem 
Cell Research?” (2010) 7:1 Cell Stem Cell 25 [Bubela et al, 
“Commercialization and Collaboration”]; Sotaro Shibayama, John P 
Walsh & Yasunori Baba, “Academic Entrepreneurship and Exchange of 
Scientifi c Resources: Material Transfer in Life and Materials Sciences in 
Japanese Universities” (2012) 77:5 American Sociological Review 804; 
Shawn HE Harmon, Timothy Caulfi eld & Yann Joly, “Commercialization 
Versus Open Science: Making Sense of the Message(s) in the Bottle” 
(2012) 12:1 Medical Law International 3.
12. Christine R Critchley, Gordana Burce & Matthew Farrugia, “Th e 
Impact of Commercialization on Public Perceptions of Stem Cell 
Research: Exploring Diff erences Across the Use of Induced Pluripotent 
Cells, Human and Animal Embryos” (2013) 9:5 Stem Cell Reviews & 
Reports 541; Christine R Critchley & Dianne Nicol, “Understanding 
the Impact of Commercialization on Public Support for Scientifi c 
Research: Is it about the Funding Source or the Organization Conducting 
the Research?” (2011) 20:3 Public Understanding of Science 347; 
M Norton Wise, “Th oughts on the Politicization of Science through 
Commercialization” (2006) 73:4 Social Research 1253; Ubaka Ogbogu & 
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(especially in innovative fi elds that have captured public attention and 
purse strings, such as genetics and stem cell research),13 and neglect of 
basic research programs. 14 Th e latter concern has generated some push 
Amy Zarzeczny, “Ethical, Legal and Social Implications of Translational 
Stem Cell Research: Eff ects of Commercialization on Public Opinion 
and Trust of Stem Cell Research” in Kristina Hug & Göran Hermerén, 
eds, Translational Stem Cell Research: Issues Beyond the Debate on the Moral 
Status of the Human Embryo (New York: Humana Press, 2011) 341; 
Deborah Zucker, “Ethics and Technology Transfer: Patients, Patents, 
and Public Trust” (2011) 59:5 Journal of Investigative Medicine 762; 
Christine R Critchley, “Public Opinion and Trust in Scientists: Th e Role 
of the Research Context, and the Perceived Motivation of Stem Cell 
Researchers” (2008) 17:3 Public Understanding of Science 309.
13. Caulfi eld, “Economic Promises”, supra note 1; Tania Bubela et al, 
“Is Belief Larger than Fact: Expectations, Optimism and Reality for 
Translational Stem Cell Research” (2012) 10:1 BMC Medicine 133; 
Zubin Master & David B Resnik, “Hype and Public Trust in Science” 
(2013) 19:2 Science and Engineering Ethics 321; Zubin Master & David 
B Resnik, “Promoting Public Trust: ESCROs Won’t Fix the Problem 
of Stem Cell Tourism” (2013) 13:1 American Journal of Bioethics 53; 
James Porter et al, “On Being a (Modern) Scientist: Risks of Public 
Engagement in the UK Interspecies Embryo Debate” (2013) 31:4 New 
Genetics and Society 408; T Caulfi eld & C Condit, “Science and the 
Sources of Hype” (2009) 15:3-4 Public Health Genomics 209; Cong 
Cao, Richard P Appelbaum & Rachel Parker, “‘Research is High and the 
Market is Far Away’: Commercialization of Nanotechnology in China” 
(2013) 35:1 Technology in Society 55; Michael P Messenger & Paul E 
Tomlins, “Regenerative Medicine: A Snapshot of the Current Regulatory 
Environment and Standards” (2011) 23:12 Advanced Materials H10.
14. Laura Eggertson, “Scientists, Supporters Rally in Canadian Cities to 
Support Basic Research” (2013) 185:15 Canadian Medical Association 
Journal E707; Shirley Leitch et al, “Th e Fall of Research and Rise 
of Innovation: Changes in New Zealand Science Policy Discourse“ 
(2014) 41:1 Science and Public Policy 119; Gürol Irzik, “Why Should 
Philosophers of Science Pay Attention to the Commercialization of 
Academic Science?” in Mauricio Suárez, Mauro Dorato & Miklós Rédei, 
eds, EPSA Epistemology and Methodology of Science (Dordrecht: Springer 
Netherlands, 2010) 129; Leland L Glenna et al, “Commercial Science, 
Scientists’ Values, and University Biotechnology Research Agendas” 
(2011) 40:7 Research Policy 957; Lee Davis, Maria Th eresa Larsen & 
Peter Lotz, “Scientists’ Perspectives Concerning the Eff ects of University 
Patenting on the Conduct of Academic Research in the Life Sciences” 
(2011) 36:1 Journal of Technology Transfer 14; Hanna Hottenrott & 
Susanne Th orwarth, “Industry Funding of University Research and 
Scientifi c Productivity” (2011) 64:4 Kyklos 534; Dominique Foray & 
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back from the scientifi c community. For example, this past September, 
over 200 Canadian university researchers rallied at the nation’s capital in 
Ottawa to express dismay over government neglect of basic research in 
favour of applied research programs and grants “that specify industrial 
partnerships or are directed at solving applied research problems or at 
increasing innovation and commercialization.”15
As the debate rages on, there remains a considerable lack of clarity 
regarding the true nature and scope of this “commercialization creep,”16 
where the pressure comes from and the nature of the pressure it supposedly 
exerts on scientists and the scientifi c research environment. No studies 
have explored, for instance, the actual sources of the commercialization 
ethos or the language employed to express or justify the push or pressure 
to commercialize science. Similarly, with the exception of studies that 
have investigated the impact of commercialization trends on the scientifi c 
research environment, much remains unknown about how the scientifi c 
research community views this trend or pressure or about the impact 
of existing commercialization programs on the conduct or culture of 
scientifi c research. 17 
Francesco Lissoni, “University Research and Public-Private Interaction” in 
Bronwyn H Hall & Nathan Rosenberg, eds, Handbook of Th e Economics 
of Innovation, vol 1 (Amsterdam: Elsevier, 2010) 275; James A Evans, 
“Industry Induces Academic Science to Know Less about More” (2010) 
116:2 Americal Journal of Sociology 389; Ferric C Fang & Arturo 
Casadevall, “Lost in Translation – Basic Science in the Era of Translational 
Research” (2010) 78:2 Infection and Immunity 563; Martin Carrier, 
“Knowledge, Politics, and Commerce: Science Under the Pressure of 
Practice” in Martin Carrier & Alfred Nordmann, eds, Science in the 
Context of Application (Amsterdam: Springer Netherlands, 2011) 11; 
Daniel H Nickolai, Steve G Hoff man & Mary Nell Trautner, “Can a 
Knowledge Sanctuary also be an Economic Engine? Th e Marketization of 
Higher Education as Institutional Boundary Work” (2012) 6:3 Sociology 
Compass 205.
15. Eggertson, ibid at E708.
16. Caulfi eld, “Commercialization Creep”, supra note 1. 
17. Bubela et al, “Commercialization and Collaboration”, supra note 
11; Glenna et al, supra note 14; Timothy Caulfi eld et al, “Patents, 
Commercialization and the Canadian Stem Cell Research Community” 
(2008) 3:4 Regenerative Medicine 483 [Caulfi eld et al, “Patents”]; CJ 
Murdoch & Timothy Caulfi eld, “Commercialization, patenting and 
genomics: researcher perspectives” (2009) 1:2 Genome Medicine 22; 
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In Canada, there are several well-known examples of the degree 
to which the political rhetoric has translated into tangible changes in 
the way research is funded, such as the Alberta Government’s decision 
to create the commercialization-focused Alberta Innovates (which 
replaced the more research oriented Alberta Heritage Foundation for 
Medical Research), and the federal government’s recent push to more 
closely align the work of National Research Council with the needs of 
industry. 18 However, despite the high profi le nature of these examples, 
much remains unclear, such as the degree to which political commentary 
about the commercialization imperative has penetrated formal research 
funding requirements and expectations and, if it has, how that change is 
explicitly justifi ed.19
In this article, we seek to address some of these gaps through a 
comprehensive review of over one hundred relevant Canadian documents 
identifi ed through database searches, including legislation; government 
policy instruments; funding agencies’ program and awards guides and 
policy statements; political commentary; and university policies. We seek 
Yann Joly et al, “Th e Commercialization of Genomic Research in Canada” 
(2010) 6:2 Health Policy 24; Valentina Tartari & Stefano Breschi, “Set 
Th em Free: Scientists’ Evaluations of the Benefi ts and Costs of University-
Industry Research Collaboration” (2012) 21:5 Industrial and Corporate 
Change 1117.
18. Eggertson, supra note 14; Carol Goar, “How to Modernize Canada’s 
Science Policy; Report sees National Research Council as a Bridge 
between Science and Industry”, Toronto Star (17 June 2013) A15; Peter 
Howitt, “Let Curiosity Drive Commerce”, Th e Globe and Mail (6 June 
2013) A17; Ivan Semeniuk, “Budget Ignites Science Debate; Questions 
Arise over Merits of Basic and Applied Research as Government Tables 
Funding Allocations”, Th e Globe and Mail (25 March 2013) A4; National 
Research Council Canada, News Release, “Open for Business: Refocused 
NRC will Benefi t Canadian Industries; Th e Government of Canada 
Launches Refocused National Research Council” (7 May 2013) online: 
National Research Council Canada <http://www.nrc-cnrc.gc.ca/eng/news/
releases/2013/nrc_business.html>.
19. Eggertson, supra note 14; Goar, ibid; Howitt, ibid; Semeniuk, ibid; C 
Scott Findlay, “Big Boasts, Little Proof; Ottawa Claims it has Provided 
Unprecedented Support for Science. Th e Evidence says Otherwise”, 
National Post (8 April 2013) A14; Mia Rabson, “Federal Cuts Dubbed 
‘Attack on Acience’ – Researchers to Protest with ‘Funeral Procession’”, 
Winnipeg Free Press (10 July 2012) B3.
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to identify and thematically assess concrete sources of and justifi cations 
for the commercialization push in the context of the Canadian research 
environment. However, we also briefl y highlight emerging empirical 
evidence on the impact of existing commercialization programs on 
the conduct or culture of scientifi c research and on the views of the 
Canadian scientifi c research community regarding the push or pressure 
to commercialize their work. 
II.  Sources of and Justifi cations for the    
 Commercialization Imperative
We explored documents from Canada’s federal and provincial research 
funding agencies, from relevant publicly funded research non-profi t 
organizations (e.g. Genome Canada), and from relevant research 
institutions (e.g. universities). In short, we sought to identify and analyze 
any language that could be interpreted as creating commercialization 
pressure within the Canadian research environment. We found that 
this ethos was ubiquitous. References to the imperative need to 
commercialize scientifi c research and justifi cations for doing so exist in 
most of the documents we reviewed, and permeate virtually all sources of 
governmental and institutional science and funding policy. 
Specifi cally, the pursuit of commercialization is mandated by 
federal and provincial legislation governing Canada’s research funding 
agencies. For example, the Canadian Institutes for Health Research 
(CIHR), the primary health research funding agency, is directed by 
legislation to “facilitat[e] the commercialization of health research … and 
promot[e] economic development through health research.” 20 Similarly, 
legislation governing National Research Council Canada (Canada’s 
premier organization for research and development) and key provincial 
research policy and funding institutions such as Alberta Innovates; 
British Columbia’s Innovation Council; Nova Scotia’s Innovation 
Corporation; and New Brunswick’s Research and Innovation Council 
variously mandate a focus on the following objectives: translating 
research knowledge into clinical applications; promoting research that 
20. Canadian Institutes of Health Research Act, SC 2000, c 6, s 4(i).
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will result in the formation of new industries or expansion of existing 
ones; establishment of funding programs specifi cally aimed at applied 
research; job creation; “promot[ing] industrial, economic and social 
development”; and translating research knowledge into lofty goals such 
as improving Canadians’ quality of life and creating value for Canadians 
(see Table A for more examples). 21
Beyond the realm of law and high-level policy, similar references and 
justifi cation abound in the other sources reviewed, notably in research 
funding documents, granting peer review policies, and university 
policies (see Table B for specifi c examples of funding and institutional 
statements). CIHR’s Grant and Awards Guide, for instance, includes 
a provision that requires applicants for research funding to “endeavour 
to obtain the greatest possible economic benefi t to Canada from any 
commercial activity resulting from research fi ndings.”22 Genome 
Canada’s Guidelines for Funding Research Projects states that grant 
applicants “must describe, with supporting evidence, the deliverable(s) 
that will be realized by the end of the project that will lead to social 
and/or economic benefi ts for Canada.”23 Similar language is present in 
the advertised funding opportunities included in our review, with some 
opportunities requiring applicants to demonstrate that their research will 
“accelerate commercialization”; “foster an entrepreneurial culture within 
and around the health research community”;24 and facilitate “commercial 
21. British Columbia Innovation Council Act, RSBC 1997, c 415, s 3; National 
Research Council Act, RSC 1985, c N-15; Alberta Research and Innovation 
Act, SA 2009, c A-31.7; Innovation Corporation Act, SNS 1994-95, c 5; 
New Brunswick Research and Innovation Council Act, SNB 2013, c 5.
22. Canadian Institutes of Health Research, “CIHR Grants and Awards 
Guide” (1 April 2013), online: Canadian Institutes of Health Research 
<http://www.cihr-irsc.gc.ca/e/805.html>.
23. Genome Canada, “Guidelines for Funding Research Projects” (June 
2012), online: Genome Canada <http://www.genomecanada.ca/medias/
PDF/en/2012-bcb-competition-guidelines.pdf> at 6.
24. Canadian Institutes of Health Research, “Proof of Principle: Phase I (Fall 
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development of products”25 (see List A for more examples).
On the institutional side, universities in the Province of Alberta 
are required to allocate institutional resources in a manner that ensures 
“excellence in research, innovation, and commercialization” and that 
the province’s economy “is competitive and sustainable,”26 while the 
University of Toronto views research commercialization, specifi cally, 
translating research results “into products and processes with economic 
and social benefi t” as “an important measure of impact beyond the 
University”27 (see List B for more examples). Th ese statements and 
policies express and govern the granting and institutional requirements 
and expectations facing researchers, and operate informally as indicators 
of successful research careers. 
Viewed as a whole, our review confi rms the presence of systemic and 
systematic pressure on Canadian researchers to commercialize research 
outcomes. Th e overall message appears to be that commercialization 
is now a central element and goal of the scientifi c research enterprise. 
Indeed, in the past decade, the federal and provincial governments have 
allocated signifi cant public resources to shifting the focus of Canadian 
science towards this commercialization ethos. 28 At the federal level, 
several initiatives and programs specifi cally devoted entirely to research 
commercialization have emerged in recent years, including the Centres 
of Excellence for Commercialization and Research program (annual 
budget: $30m) and the Business-Led Networks of Centres of Excellence 
25. Alberta Innovates – Health Solutions, “AIHS Knowledge-to-Action 
Grant” (2013), online: Alberta Innovates – Health Solutions <http://
www.aihealthsolutions.ca/rtna/grant.php>.
26. Government of Alberta, “Draft Letter of Expectation between the 
Minister of Alberta Enterprise and Advanced Education and the Board 
of Governors of the University of Alberta”, online: Change@UAlberta 
<http://change.ualberta.ca/-/media/change/letter-of-expectation---u-of-a/
letter-of-expectation---u-of-a.pdf>. 
27. University of Toronto, “University of Toronto Performance Indicators 
2012: Our Research Excellence – Innovation and Commercialization”, 
online: University of Toronto <http://www.utoronto.ca/__shared/assets/
A_05_a-c_Innovation_Commercialization4920.pdf>.
28. Einar Rasmussen, “Government Instruments to Support the 
Commercialization of University Research: Lessons from Canada” (2008) 
28:8 Technovation 506.
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program (annual budget: $12m), both of which channel publicly 
funded university research towards the commercialization pipeline and 
to responding to challenges identifi ed by industry. Th e provinces have 
established similar programs, including Alberta Innovates – Health 
Solutions, which supports research activities that “create … health related 
social and economic benefi ts for Albertans,”29 and Fonds de recherche 
Santé Québec, a Québec government-backed funding initiative designed 
to support scientifi c and technological research that will “contribute to 
Québec’s economic growth,”30 among other things.
Our review also revealed a number of justifi cations for the push to 
commercialize, including enabling improved health care and quality of 
life; making the innovation system more sustainable (economically); 
faster product development; creation of new industries and expansion 
of existing ones; realizing returns on research investments; accountability 
to taxpayers; promoting economic growth and social development; 
job creation; and creating value for Canadians. Th ese justifi cations 
were typically expressed in broad, aspirational language, with little or 
no explanation regarding meaning, scope or how they can be achieved 
in practical terms. Put diff erently, the justifi cations are presented in a 
manner that suggests they are obvious endpoints. Th e presentation also 
does not provide any evidence to support the suggested link between 
research commercialization and the stated justifi cations (this is a topic 
for further research), nor are there, in most cases, identifi ed metrics for 
measuring successful outcomes for each of the stated justifi cations.31 
Also worrisome, from a policymaking perspective, there is no mention 
of the potential downsides or risks of commercialization.  Th is side of 
the policy debate is completely absent from national, provincial and 
institutional science funding policy. Given the evidence of possible risks, 
this is a troubling absence as one would hope that emerging policy would 
29. Alberta Innovates – Health Solutions, “Mandate and Roles Document” 
(April 2010), online: Alberta Innovates – Health Solutions <http://www.
aihealthsolutions.ca/docs/mandate%20and%20roles.pdf> at 1.
30. Fonds du recherche du Québec – Santé, “FRQS Mission” (25 November 
2004), online: FRQS <http://www.frsq.gouv.qc.ca/en/a_propos/popup/
mission_integrale.html>.
31. Rasmussen, supra note 28.
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explicitly recognize and balance both potential benefi ts and risks.
III. Brief Highlights of Emerging Evidence on   
 Community Reaction and Impacts on Research  
 Environment
Existing studies from Canada and elsewhere have observed a disconnect 
between policy and practice with respect to commercialization of publicly 
funded research. For example, a recent study found that professionals 
working in Canadian Technology Transfer Offi  ces (TTOs) view their 
practical role as supporting the social and academic missions of their 
universities rather than their primary mandate, which is to promote 
and achieve research commercialization targets.32 Another study found 
that commercialization activities (chiefl y patenting) by members of the 
Stem Cell Network impact negatively on their collaborative behaviour 
(specifi cally, co-authorship), which is, arguably, an incidental outcome of 
the Network’s commercialization-driven research approach and mandate.33 
Similarly, a study of technology commercialization via licensing contracts 
between US universities and the life sciences industry found evidence of 
the so-called “anticommons” eff ect;34 specifi cally, that exclusive licensing 
of patented technologies to single fi rms had a “dampening eff ect” on 
“innovation diff usion” by reducing researchers’ propensity to publish or 
collaborate with others.35 Th e pressure to commercialize has also been 
linked to secretive behaviour among academic scientists and with creating 
disincentives to information sharing,36 and with having undesirable 
32. Tania M Bubela & Timothy Caulfi eld, “Role and Reality: Technology 
Transfer at Canadian Universities” (2010) 28:9 Trends in Biotechnology 
447.
33. Bubela et al, “Commercialization and Collaboration”, supra note 11.
34. Michael A Heller & Rebecca S Eisenberg, “Can Patents Deter Innovation? 
Th e Anticommons in Biomedical Research” (1998) 280:5364 Science 
698.
35. Joshua B Powers & Eric G Campbell, “Technology Commercialization 
Eff ects on the Conduct of Research in Higher Education” (2011) 52:3 
Research in Higher Education 245.
36. Wei Hong & John P Walsh, “For Money or Glory? Commercialization, 
Competition, and Secrecy in the Entrepreneurial University” (2009) 50:1 
Th e Sociological Quarterly 145.
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eff ects on the quantity and quality of research outputs.37
Regarding community reaction, a number of published studies have 
shed some light on the views and perspectives of the scientifi c research 
community on the push to commercialize research.38 A recent nation-
wide study of US biotechnology scientists found a “strong positive 
association” between market-driven views and values and the tendency 
to pursue applied research programs, and that this association directly 
aff ects industry funding, the proprietary nature of research outputs, and 
the degree of focus on basic research programs.39 Similarly, surveys of 
Canadian genomics and stem cell researchers reveal that while views 
regarding commercialization and patenting pressure are sharply divided 
between supportive and critical, such pressures are correlated with 
an increased tendency to engage in data withholding practices and 
publication delays.40
A recent informal sampling of the views of members of the Canadian 
Stem Cell Network regarding commercialization pressure – conducted 
by our research team for the primary purpose of informing proposed 
semi-structured interviews – adds some colour to the existing evidence.41 
Th e Network is one of Canada’s Networks of Centres of Excellence 
(NCEs), a funding initiative established in 1989 by Canada’s three major 
research funding agencies (CIHR; the National Sciences and Engineering 
Research Council, which funds research in the natural sciences 
and engineering; and the Social Sciences and Humanities Research 
Council, which funds research in the social sciences and humanities) in 
collaboration with Health Canada and Industry Canada.42 NCEs unite 
37. Hottenrott & Th orwarth, supra note 14.
38. Glenna et al, supra note 14; Caulfi eld et al, “Patents”, supra note 17; 
Murdoch & Caulfi eld, supra note  17; Joly et al, supra note 17; Tartari & 
Breschi, supra note 17.
39. Glenna et al, supra note 14.
40. Caulfi eld et al, “Patents”, supra note 17; Murdoch & Caulfi eld, supra note 
17.
41. Ubaka Ogbogu, Amir Reshef & Timothy Caulfi eld, “Under Pressure? 
Stem Cell Research and the Commercialization Imperative” (Poster 
presentation delivered at the Canadian Stem Cell Network Till and 
McCulloch Meetings, Banff  Springs Hotel, Banff , 23-25 October 2013) 
[unpublished].
42. Ogbogu, supra note 8; Donald Fisher, Janet Atkinson-Grosjean & Dawn 
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Canada’s leading researchers in a fi eld of common interest, with the 
aim and mandate to “commercialize and apply … homegrown research 
breakthroughs, increase private-sector R&D, and train highly qualifi ed 
people.”43 SCN is one of the program’s success stories, and has received 
over $82m since it was created in 2001. Th e Network’s primary mandate 
is to “be a catalyst for enabling translation of stem cell research into 
clinical applications, commercial products or public policy.”44
We learned that many in the community are wary of current 
commercialization trends and are concerned about its eff ects on the 
scientifi c research environment. Specifi cally, most members reported 
that they face considerable pressure to commercialize and/or translate 
their research in the near term and that it would be more diffi  cult to 
secure research funding without proposing a commercialization and/or 
translation plan. Th ey identifi ed main sources of pressure to commercialize 
as including granting agencies, patient/disease advocacy groups, their 
universities, and the government. Members expressed concern that 
commercialization trends will adversely aff ect research funding and 
opportunities for pursuing basic research, and that public trust in research 
will be compromised if the promised benefi ts of commercialization do 
not materialize in the near term or at all. Th ey felt that commercialization 
and/or research translation targets were more likely to materialize in the 
longer rather than short term, and that the most important outcome they 
expect from their research are scholarly publications. Th ese observations, 
which we caution are neither representative of the views of this community 
nor intended to serve as robust evidence of such views, do suggest the 
possibility that research communities primed for commercialization may 
hold an unfavourable or unenthusiastic view of their commercialization 
mandate, and may perceive this mandate to be associated with undesirable 
House, “Changes in Academy/Industry/State Relations in Canada: Th e 
Creation and Development of the Networks of Centres of Excellence” 
(2001) 39:3 Minerva 299.
43. Networks of Centres of Excellence, “About the Networks of Centres of 
Excellence” (17 October 2013), online: Networks of Centres of Excellence 
<http://www.nce-rce.gc.ca/About-APropos/Index_eng.asp>.
44. Networks of Centres of Excellence, “Stem Cell Network – SCN” (4 April 
2013), online: Networks of Centres of Excellence <http://www.nce-rce.
gc.ca/NetworksCentres-CentresReseaux/NCE-RCE/SCN-RCS_eng.asp>. 
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social and research-related costs, such as loss of public trust in research 
and loss of opportunities for research funding and basic research. Th ey 
also prompt questions about whether scientists’ expectations are aligned 
with policies urging aggressive commercialization of the research. 
IV.  Conclusion
Our analysis illustrates the degree to which the commercialization 
imperative has become near universal. Th ere is almost no place within 
the Canadian research-funding environment that is not touched by 
the commercialization ethos. And there is, at least within the policy 
documents themselves, very little substantive justifi cation for this shift. 
Indeed, its value is presented as axiomatic and universally accepted – 
which, given the recent protests in Canada by researchers, is clearly not 
the case.  More worrisome, at least from the perspective of transparent 
policymaking, there is virtually no explicit mention of the potential costs 
and harms associated with the push to commercialize. Few would argue 
that there are not benefi ts to the commercialization of research or with 
links to industry.  But research tells us there are trade-off s, including a 
loss of public trust, decreased collaborative behaviour and, possibly, the 
premature implementation of technologies.  
Given these downsides, one would hope that there would be explicit 
reference to evidence regarding the purported social benefi ts of this 
trend, but this too, as noted, is missing. Regardless of how one views such 
ambitious and unsubstantiated promotion of research commercialization, 
it should prompt serious questions about whether scientists and the 
scientifi c research infrastructure can presently deliver the promised 
benefi ts, and whether achieving such benefi ts is justifi ed in light of the 
possible social costs of the trend. Th at said, interesting questions remain, 
including whether this pressure actually changes researcher behaviour 
and the direction of research. Perceptions and fears aside, scientists may 
simply adapt to the new environment in nimble fashion, and realign 
their research agendas accordingly.
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Table A: Examples of Commercialization Language in Legislation 
(continued on next page)
Source   Reference
Canadian Institutes “Th e objective of the CIHR is to excel … in the 
of Health Research creation of new knowledge and its translation into
Act   improved health for Canadians, more eff ective
   health services and products … by … facilitating
   the commercialization of health research in Canada
   and promoting economic development through
   health research in Canada”45
National Research  “Council may … undertake, assist or promote
Council Act  scientifi c and industrial research, including …
   researches with the object of improving the technical
   processes and methods used in the industries
   of Canada, and of discovering processes and
   methods that may promote the expansion of existing
   or the development of new industries”46
Alberta Research   “Th e purpose of this Act is to promote and provide
and Innovation Act for the strategic and eff ective use of funding and
   other resources to meet the research and innovation
   priorities of the Government, including fostering
   the development and growth of new and existing
   industries”47
New Brunswick  “Council shall advise and make recommendations
Research and  to the Executive Council on all aspects of research
Innovation Council and innovation and on the development and
Act   commercialization of technology in order to
   advance these activities in New Brunswick and to
   foster … increased collaboration between
   government and the business, industry, post
   secondary education and research communities”48
Innovation  “Th e objects of the Corporation are to … mobilize
Corporation Act   the necessary resources, nationally and
(Nova Scotia)  internationally, to allow for technological
   development and commercialization in priority  
   technology areas defi ned by the Corporation”49 
45. Supra note 20, s 4.
46. Supra note 21, s 5(c).
47. Supra note 21, s 2.
48. Supra note 21, s 7.
49. Supra note 21, s 5(a).
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Economic Innovation  “Th e objects of the council are to foster economic
and Technology   development and to support economic restructuring
Council Act   through innovation and the development and
(Manitoba)  commercialization of technology so as to enable
   Manitoba to compete eff ectively in a global market
   economy”50
List A: Examples of Commercialization Requirements in Funding 
Opportunities (continued on next page)
• CIHR Open Operating Grant, 2013-2014: Grants are expected to 
“[c]ontribute to commercialization/ knowledge translation”51
• Alberta Innovates – Alberta/Pfi zer Translational Research Fund Opportunity 
(June 2013): “Th e funding opportunity will focus on the development and 
commercialization of innovations in health that support the interests and 
priorities of Alberta and Pfi zer and serve as a catalyst for innovative research 
in Alberta”52
• Alberta Innovates – Knowledge-to-Action Grant (2013): “Grant 
opportunity is intended to support the uptake of research evidence into 
health policy, practice and commercial development of products”53
• Ontario Research Fund – Early Researcher Awards Program Guidelines 
(March 2013): Applications must demonstrate “potential for strategic value 
for Ontario based on … economic benefi ts [and] entrepreneurial focus”54
• Innovation PEI – Pilot and Discovery Fund Program Guidelines (2013): 
Proposed project must “[d]evelop a product or service that demonstrates 
a high level of innovation, commercial viability, and market potential … 
[and] [c]reate a positive economic impact for the Province (jobs, economic 
spin-off s, etc.)”55
50. Th e Economic Innovation and Technology Council Act, CCSM c E7, s 3.
51. Canadian Institutes of Health Research, “CIHR Open Operating Grant” 
(19 June 2013), online: ResearchNet <https://www.researchnet-recherch 
enet.ca/rnr16/vwOpprtntyDtls.do?prog=1873&view=search&terms=com 
mercialization&org=CIHR&type=EXACT&resultCount=25>.
52. Alberta Innovates – Health Solutions, “Alberta/Pfzer Translational 
Research Fund Opportunity” (June 2013), online: Alberta Innovates 
– Health Solutions <http://www.aihealthsolutions.ca/grants/industry-
partnered-translational-fund/pfi zer/docs/AB-Pfi zer-Program-Guide%20
2013-07.pdf>.
53. Alberta Innovates – Health Solutions, “AIHS Knowledge-to-Action 
Grant” (2013), online: Alberta Innovates – Health Solutions <http://
www.aihealthsolutions.ca/rtna/grant.php>.
54. Ontario Research Fund, “Early Researcher Awards Program Guidelines” 
(March 2013), online: <http://docs.fi les.ontario.ca/documents/275/medi-
era-round-9-program-guidelines.pdf>.
55. Innovation PEI, “Pilot and Discovery Fund: Program Guidelines” (2013), 
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• Ontario Genomics Institute – Pre-Commercialization Business 
Development Fund (2013): “[U]nique and useful investment fund that 
is helping to enable the economic impact of outcomes of genomics and 
proteomics research projects and technology development. Specifi cally, it 
aims to provide early-stage funding as researchers move towards commercial 
applications and to speed up transfer of products from lab to marketplace”56
• CIHR Operating Grant – Industry-Partnered Collaborative Research (Fall 
2013): Objective of funding opportunity includes to “promote economic 
development through health research in Canada” and “encourage and 
facilitate mutually benefi cial university-industry collaborations in health 
research”57
• Canadian Foundation for Innovation – 2012 Leading Edge and New 
Initiatives Funds Competition: “Th e research or technology development 
enabled by CFI funding creates the necessary conditions for sustainable, 
long-term economic growth, including the creation of spin-off  ventures and 
the commercialization of discoveries. It supports improvements to society, 
quality of life, health, the environment, and public policy”58
List B: Examples of Commercialization Language in University 
Documents (continued on next page)
• University of Toronto (2013): “U of T is a leading university in Canada for 
commercialization and entrepreneurship and is a global leader in turning 
ideas and innovations into products, services, companies and jobs.”59
• University of Alberta (2013): “UAlberta benefi ts society by transferring 
research, knowledge and discoveries out of the institution and into the 
community. One way to ensure UAlberta research solutions have the greatest 
online: Innovation PEI <http://www.gov.pe.ca/photos/original/IPEI-Pilot-
Guid.pdf>.
56. Ontario Genomics Institute, “Pre-commercialization Business 
Development Fund” (2013), online: Ontario Genomics Institute <http://
www.ontariogenomics.ca/business-development/pre-commercialization-
business-development-fund>.
57.      Canadian Institutes of Health Research, “Operating Grant: Industry-Part               




58. Canada Foundation for Innovation, “2012 Leading Edge and New 
Initiatives Funds Competition” (September 2011), online: Canada 
Foundation for Innovation <http://www.innovation.ca/sites/default/fi les/
Funds/Call-LEFNIF2012_EN.pdf>.
59. University of Toronto Research and Innovation, “Commercialization at 
U of T” (2013), online: University of Toronto <http://www.research.
utoronto.ca/industry-and-partners/commercialization-at-u-of-t/#top>.
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reach and impact on both society and the economy is commercialization.”60
• University of Alberta (2013): “Th e University actively transfers new 
knowledge and creative works to Alberta, Canada and the world for 
community benefi t, including commercial development of intellectual 
property when appropriate and feasible”61
• University of British Columbia: “For transformational research discoveries 
with the potential to generate signifi cant impacts, whether fi nancial, 
economic, or societal, the traditional technology transfer approach of IP-
protection, development and commercialization will frequently remain 
essential.”62
• McGill University (2013): “Th e commercialization of research outcomes 
is an important objective not just of researchers, but of most public and 
private funding programs as well. It can also be very rewarding, with 
potential impact on society, the economy and the environment at large”63
• University of Saskatchewan (2011): “We want to ensure that the relationships 
created through the commercialization of a technology continue to add 
value for all partners; leading to ongoing research projects for the inventor 
and the industry partner and to the commercialization of complementary 
technologies”64
• Queen’s University (2013): “Th e role of Innovation Park is to foster 
interaction among the participants in the research and innovation system 
and thus stimulate commercialization and economic development in the 
South Eastern Ontario region.”65
• University of Calgary (1994): “Th e nature and scope of University scholarly 
activity is such that industrially useful and/or commercially valuable 
60. University of Alberta Research, “Commercialization” (2013), 
online: University of Alberta <http://www.research.ualberta.ca/
MobilizingKnowledge/Commercialization.aspx>.
61. University of Alberta Board of Governors, “Mandate and Roles 
Document” (2013), online: University of Alberta <http://www.
governance.ualberta.ca/~/media/Governance/Documents/GO09/MAN/
Mandates_and_Roles-_Approved_October_2011.pdf>.
62. University of British Columbia University-Industry Liaison Offi  ce, 
“Technology Transfer/Commercialization”, online: University of British 
Columbia <http://www.uilo.ubc.ca/uilo/knowledge-mobilization/
channels/commercialization>.
63. McGill Research and International Relations, “Managing Your Intellectual 
Property” (2013), online: McGill <http://www.mcgill.ca/research/
researchers/ip>.
64. University of Saskatchewan, “Industry Liaison – Who Are We?” (2013), 
online: University of Saskatchewan <http://www.usask.ca/research/ilo/
whoweare.php>.
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Intellectual Property is sometimes the result. Indeed, there is a societal 
expectation that University scholarly activities will include activities which, 
applied, lead to useful outcomes.”66
Table B: Examples of Commercialization Language in Political/
Institutional Commentary (continued on next two pages)
Source   Reference
National Research  “We are committed to being a strong partner for
Council (2013)  innovation, and focused on achieving the concrete
   outcomes that will contribute to a stronger and
   more prosperous Canada. We will measure our
   success by the success of our clients.”67
Minister of State   “Capitalizing on the momentum generated by …
Gary Goodyear   investments [in research], we will continue to
(Industry Canada  improve commercialization performance by
2013)   transforming research outcomes into economic
   benefi ts for Canadians”68
Canadian Institutes  “Th rough its commercialization and innovation
of Health Research  strategy, CIHR will continue to catalyze
(2009)   collaborations between industry and the research
   community to translate health research into
   improved health products, technologies, tools and  
   services”69
Networks of Centres  “Th e goal of the NCE Program is to mobilize
of Excellence (2011) Canada’s research talent in the academic, private,
   public, and not-for-profi t sectors and apply it to the 
   task of developing the economy and improving the
   quality of life of Canadians.”70
66. University of Calgary, “Intellectual Property Policy” (2014), online: 
University of Calgary <http://www.ucalgary.ca/policies/fi les/policies/
Intellectual%20Property%20Policy.pdf>.
67. National Research Council Canada, supra note 18.
68. Industry Canada, News Release, “Minister of State Goodyear Promotes 
Commercialization of Canadian Research at International Forum” (19 
March 2013) online: Government of Canada <http://news.gc.ca/web/
article-en.do?nid=727519>.
69. Canadian Institutes of Health Research, “Health Research Roadmap: 
Creating Innovative Research for Better Health and Health Care”, 
online: Canadian Institutes of Health Research <http://www.cihr-irsc.
gc.ca/e/40490.html>.
70. Networks of Centres of Excellence of Canada, “Program Guide” (2011), 
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Centres of Excellence  “Th e innovative … program bridges the challenging
for Commercialization  gap between innovation and commercialization.
and Research Program  Th e program matches clusters of research expertise
(2013)   with the business community to share the knowledge
   and resources that bring innovations to market  
   faster.”71
Centre for   “CCRM represents a tremendous opportunity for
Commercialization  Canadians to lead RM commercialization …
of Regenerative   CCRM engages industry partners, making CCRM
Medicine (2011)  a global hub of RM commercialization and
   attracting investment to Ontario, leading to new
   jobs and economic growth.”72
Government of   “Canada must translate knowledge into commercial
Canada (2007);  applications that generate wealth for Canadians and
   support the quality of life we all want in order to
   create an Entrepreneurial Advantage.”73
2009   “Canada’s ability to gain a competitive advantage in
   the modern economy increasingly depends on our
   ability to translate knowledge and ideas into
   commercial products.”74
Innovate Nova   “Th e Innovate Nova Scotia policy framework has
Scotia (2009)  been developed to stimulate awareness of and
   discussion on the importance of maximizing the
   impact of innovation to enhance economic growth
   and employment in this province.”75
online: Networks of Centres of Excellence <http://www.nce-rce.gc.ca/
ReportsPublications-RapportsPublications/NCE-RCE/ProgramGuide-
GuideProgramme_eng.asp>.
71. Networks of Centres of Excellence of Canada, “Centres of Excellence for 
Commercialization and Research Program” (2013), online: Networks of 
Centres of Excellence <http://www.nce-rce.gc.ca/Programs-Programmes/
CECR-CECR/Index_eng.asp>.
72. Centre for Commercialization of Regenerative Medicine, “Mission” 
(2011), online: CCRM <http://ccrm.ca/mission>.
73. Industry Canada, “Mobilizing Science and Technology to Canada’s 
Advantage” (2007), online: Industry Canada <http://www.ic.gc.ca/eic/
site/icgc.nsf/eng/00871.html>.
74. Industry Canada, “Mobilizing Science and Technology to Canada’s 
Advantage: Progress Report” (2009) online: Industry Canada <http://
www.ic.gc.ca/eic/site/icgc.nsf/vwapj/STProgressReport2009.pdf/$fi le/
STProgressReport2009.pdf> at 13 [emphasis added].
75. Nova Scotia Economic Development, “Innovate Nova Scotia: An 
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Genome Canada   “Genome Canada is a catalyst for developing and
(2013)   applying genomic sciences that create economic
   wealth and social benefi t for Canadians. We work in
   partnership to invest in and manage large-scale
   research and translate discoveries into commercial
   opportunities.”76
British Columbia  “Research and innovation creates and activates the
Research and   knowledge that British Columbia needs to compete
Innovation Strategy in the global economy. It leads to new, exciting
   products and processes that help British Columbia
   prosper and raise our standard of living. It fosters
   social and economic development, creates jobs and
   supports our eff orts to address climate change and
   clean energy.”77
MaRS Innovation  “MaRS Innovation collaborates with its 16 Toronto
“How We Work”   -based member institutions … to commercialize
   market-disruptive intellectual property … Our
   mandate includes seeking opportunities to increase
   the social, health and economic benefi ts of our
   activities to Canadians and others around the   
   world.”78
Vision and Mission “To monetize the research assets found within its
   member institutions, thereby converting great science
   into commercially viable products and services”79
InnovativeNovaScotia.pdf>.
76. Genome Canada, “About Genome Canada”, online: Genome Canada 
<http://www.genomecanada.ca/en/about/>.
77. British Columbia Ministry of Advanced Education and Ministry 
Responsible for Research and Technology, “Local Excellence – Global 
Impact: BC Research and Innovation Strategy”, online: Ministry of 
Advanced Education <http://www.aved.gov.bc.ca/researchandinnovation/
Documents/strategy.pdf>.
78. MaRS Innovation, “How We Work”, online: MaRS <http://
marsinnovation.com/how-we-work/>.
79. MaRS Innovation, “Vision and Mission”, online: MaRS <http://
marsinnovation.com/about/vision/> [emphasis added].
